MIAMI BEACH, Fla., Jan. 07, 2025 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ: AIRS) (“AirSculpt” or the “Company”), an industry leader and provider of premium body contouring procedures, today announced that it will participate in investor meetings and host a presentation at the ICR Conference 2025 being held at The Grande Lakes Orlando in Orlando, Florida on January 13, 2025 through January 14, 2025.
Chief Executive Officer, Yogi Jashnani, and Chief Financial Officer, Dennis Dean, will host a presentation on Tuesday, January 14, 2025, at 10:00 a.m. Eastern Standard Time. The presentation will be webcast live at https://investors.airsculpt.com. An archive of the webcast presentation will be available for 90 days.
About AirSculpt
AirSculpt offers a next-generation body contouring treatment designed to optimize both comfort and precision, available exclusively at its 31 centers in North America and one location in the United Kingdom. The Company’s minimally invasive procedure removes fat and tightens skin, while sculpting targeted areas of the body, allowing for quick healing with minimal bruising, tighter skin, and precise results.
To learn more about AirSculpt Technologies, please visit the Company's website at https://investors.elitebodysculpture.com. AirSculpt Technologies uses its website as a channel of distribution for material Company information. Financial and other material information regarding AirSculpt Technologies is routinely posted on the Company's website and is readily accessible.
Investor Contact
Allison Malkin
ICR, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$3.32 |
| Daily Change: | -0.08 -2.35 |
| Daily Volume: | 316,584 |
| Market Cap: | US$192.160M |
December 17, 2024 November 08, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
